1. Home
  2. SONO vs MLYS Comparison

SONO vs MLYS Comparison

Compare SONO & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sonos Inc.

SONO

Sonos Inc.

HOLD

Current Price

$15.77

Market Cap

1.8B

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$25.78

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SONO
MLYS
Founded
2002
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Video Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
2.1B
IPO Year
2018
2023

Fundamental Metrics

Financial Performance
Metric
SONO
MLYS
Price
$15.77
$25.78
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
7
Target Price
$19.67
$48.67
AVG Volume (30 Days)
2.2M
742.5K
Earning Date
05-04-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
37.43
EPS
0.77
N/A
Revenue
$1,443,276,000.00
N/A
Revenue This Year
$5.04
N/A
Revenue Next Year
$6.53
N/A
P/E Ratio
$19.04
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.12
$12.59
52 Week High
$19.82
$47.65

Technical Indicators

Market Signals
Indicator
SONO
MLYS
Relative Strength Index (RSI) 53.88 39.45
Support Level $12.77 $22.36
Resistance Level $17.50 $30.90
Average True Range (ATR) 1.01 1.13
MACD 0.07 -0.24
Stochastic Oscillator 47.72 21.26

Price Performance

Historical Comparison
SONO
MLYS

About SONO Sonos Inc.

Sonos Inc is an audio company dedicated to elevating life through sound, offering a connected platform that brings together music, movies, stories, and conversations. Its portfolio includes home theater speakers, components, plug-in and portable speakers and headphones, known for exceptional sound, thoughtful design, ease of use and seamless access to audio content. Its partner products and other revenue categories include accessories for home integration, such as custom-designed stands, mounts, and shelving units, along with partnerships for architectural speakers and automotive sound systems, as well as licensing, advertising revenue, and subscription-based services. The company operates in the United States and other countries, with the majority of revenue coming from the United States.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: